Apellis Pharmaceuticals, Inc. — Director's Dealing 2019

Jan 3, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2019-01-01

Reporting Person: O'Brien Stephanie Monaghan (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-01	Stock option (right to buy)	$13.19	A	17580	Acquired	2028-12-31	Common Stock (17580)	Direct

Footnotes

F1: This option was granted on January 1, 2019 and will vest in four equal quarterly installments on April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020, subject to continued service as a director.